Single Inhaler Extrafine Triple Therapy Improves Clinical Outcomes in Gold B COPD Patients: Post-Hoc Analysis of the TRIBUTE study

Scuri, Mario; Singh, Dave; Fabbri, Leonardo M.; Guasconi, Alessandro; Vezzoli, Stefano; Prunier, H; Muraro, Annamaria; Petruzzelli, Stefano; Papi, Alberto

doi:10.1055/s-0039-1678230

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These results were consistent with those observed in TRINITY, where BDP/FF/G delayed CID compared to tiotropium, and reduced the rate of moderate/severe exacerbations in GOLD Group B patients 75,76. In TRIBUTE, in addition to confirming the delay of CID,77 and the benefits in GOLD Group B patients,78 BDP/FF/G demonstrated a favorable benefit/risk ratio compared with the dual bronchodilator combination IND/GLY;3 in particular, there was a reduced rate of moderate/severe exacerbations together with comparable rates of pneumonia events, as shown in Figure 1 79…”

Section: Review Of Triple Therapy Studiessupporting

confidence: 89%

Triple therapy (ICS/LABA/LAMA) in COPD: time for a reappraisal

Vanfleteren¹,

Fabbri²,

Papi³

et al. 2018

COPD

View full text Add to dashboard Cite

Recently, two “fixed triple” single-inhaler combinations of an inhaled corticosteroid (ICS), a long-acting β2-agonist (LABA), and a long-acting muscarinic antagonist (LAMA) have become available for patients with COPD. This review presents the clinical evidence that led to the approval of these triple therapies, discusses the role of ICS in patients with COPD, and presents data on the relative efficacy of “fixed triple” (ICS/LAMA/LABA) therapy vs LAMA, ICS/LABA, and LAMA/LABA combinations, and summarizes studies in which ICS/LABAs were combined with LAMAs to form “open triple” combinations. Of the five main fixed triple studies completed so far, three evaluated the efficacy and safety of an extrafine formulation of beclometasone dipropionate, formoterol fumarate, and glycopyrronium; the other two studies evaluated fluticasone furoate, vilanterol, and umeclidinium. Overall, compared to LAMA, ICS/LABA, or LAMA/LABA, triple therapy decreased the risk of exacerbations and improved lung function and health status, with a favorable benefit-to-harm ratio. Furthermore, triple therapy showed a promising signal in terms of improved survival. The evidence suggests that triple therapy is the most effective treatment in moderate/severe symptomatic patients with COPD at risk of exacerbations, with marginal if any risk of side effects including pneumonia. Ongoing studies are examining the role of triple therapy in less severe symptomatic patients with COPD and asthma–COPD overlap.

show abstract